



Capewell, P., Krumrie, S., Katzer, F., Alexander, C. L. and Weir, W. (2021) Molecular epidemiology of Giardia infections in the genomic era. *Trends in Parasitology*, 37(2), pp. 142-153.
(doi: [10.1016/j.pt.2020.09.013](https://doi.org/10.1016/j.pt.2020.09.013))

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/223615/>

Deposited on 29 September 2020

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>

1 **Title:** Molecular epidemiology of *Giardia* infections in the genomic era

2 **Authors:** Paul Capewell¹, Sarah Krumrie², Frank Katzer³, Claire Alexander⁴, William Weir*²

3 **Affiliations:**

4 ¹ Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical,
5 Veterinary and Life Sciences, University of Glasgow, 464 Bearsden Road, Glasgow, G61 1QH,
6 UK

7 ² School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University
8 of Glasgow, 464 Bearsden Road, Glasgow, G61 1QH, UK

9 ³ Moredun Research Institute, Pentlands Science Park, Edinburgh, EH26 0PZ, UK

10 ⁴ Scottish Parasitology Diagnostic and Reference Laboratories, Glasgow, G31 2ER, UK

11 *Correspondence: willie.weir@glasgow.ac.uk (W. Weir)

12 **Keywords:**

13 *Giardia*, genotyping, genomics, molecular epidemiology, population genetics, public health

14 **Abstract**

15 *Giardia duodenalis* is a major gastrointestinal parasite of humans and animals across the
16 globe. It is also of interest from an evolutionary perspective as it possesses many features
17 that are unique among the eukaryotes, including its distinctive binucleate cell structure.
18 While genomic analysis of a small number of isolates has provided valuable insights, efforts
19 to understand the epidemiology of the disease and the population biology of the parasite
20 have been limited by the molecular tools currently available. We review these tools and
21 assess the impact of affordable and rapid genome sequencing systems increasingly being
22 deployed in diagnostic settings. While these technologies have direct implications for public
23 and veterinary health, they will also improve our understanding of the unique biology of this
24 fascinating parasite.

25 A major worldwide pathogen

26 *Giardia duodenalis* (also known as *Giardia intestinalis* or *Giardia lamblia*) is one of the most
27 common gastrointestinal parasites in the world, causing an estimated 180 million infections
28 annually [1]. Although giardiasis is treatable, the correct administration of therapeutics
29 depends on accurately identifying the parasite, either in an individual or within a community
30 during an outbreak. Asymptomatic infection can occur and may represent the majority of
31 cases [2–5], although it should be noted that apparently asymptomatic individuals can still
32 display signs of mild malnutrition [6]. Patients with overt clinical disease experience severe
33 gastrointestinal disturbances for several weeks due to **trophozoites** (see Glossary) attaching
34 to the intestinal lining of the host, disrupting nutrient and water uptake and eliciting an
35 immune response [7]. In rare cases, some patients can develop post-infection complications
36 that lead to long-term gastrointestinal disorders similar to irritable bowel syndrome (IBS)
37 [8]. These symptoms are linked to a loss of barrier function and **dysbiosis** of the gut flora [9–
38 11]. Infective **cysts** are shed into the environment by infected hosts where they can be
39 ingested by new individuals, maintaining transmission. Outbreaks are frequently associated
40 with contaminated water [12] or food sources [13].

41 *Giardia* genetics

42 *Giardia* species are described as early divergent eukaryotes and lack common subcellular
43 structures such as mitochondria, a true Golgi complex and **peroxisomes** [14]. However, the
44 identification of mitochondrial genes in the genome suggests that *G. duodenalis* and other
45 **diplomonads** once possessed these organelles but subsequently lost them [15]. In addition
46 to being amitochondriate, *G. duodenalis* is unusual in that it possesses two nuclei despite
47 being unicellular. This gives rise to an unusual **ploidy** throughout the life-cycle where the

48 trophozoites cycle between 4N (2×2N) and 8N (4×2N) in vegetative growth, doubling to 16N
49 (4×4N) during the transition to cysts (Figure 1A) [16]. After excystation, the cell divides
50 without DNA replication to create four trophozoites, each with a ploidy of 4N. The relatively
51 small genome (11.7 megabases (Mb)) is distributed across five chromosomes that feature
52 few intergenic spaces, introns or non-coding regions. Promoters and untranslated regions
53 are also minimized, leading to a highly condensed and efficient genome [14]. This appears to
54 be a distinctive trait of the diplomonads and the genome is even more compact in the
55 closely related rodent parasite *G. muris* [17]. Although similar, the genomes of each nucleus
56 in an individual parasite are not identical and the differences between the four different
57 genomes are termed **allelic sequence heterozygosity** (ASH). The proportion of heterozygous
58 bases within a genome typically ranges between 0.25–0.74% for most *Giardia* isolates [18–
59 20] but can be extremely low (<0.01%) [9,11]. The majority of these heterozygous sites
60 contain two different bases but some feature three or four, capturing the diversity present
61 across all of the copies of the genome [20]. Regions of heterozygosity are not distributed
62 evenly throughout the genome and more typically occur in non-coding regions, as might be
63 expected with purifying selection acting on coding regions [20].

64 **Genotyping *Giardia duodenalis***

65 Initial **isozyme** and **18S ssu-rRNA gene** sequencing demonstrated that two broad groups of
66 *G. duodenalis* infected human patients (eventually termed A and B). These were
67 characterized as assemblages to reflect the fact that the relationships between the groups
68 were undefined [22–24]. Additional genetic data from animal-derived isolates, coupled with
69 various biological differences, allowed a further six distinct assemblages to be differentiated
70 (C–H) (Table 1). Assemblages A and B contain zoonotic isolates that can infect humans and

71 animals, whereas assemblages C–H show specificity to particular animal hosts (Table 1).
72 However, isolates with molecular sequences similar to assemblages C–H have been
73 amplified from humans, suggesting there are either limits to current molecular typing tools
74 or *G. duodenalis* may have a wider zoonotic potential than first assumed [25–27]. As these
75 molecular detections in humans are often from asymptomatic individuals, it is unclear
76 whether the DNA detected in the molecular screens represents infection, carriage or
77 contamination. Antigen-capture assay, immunofluorescent antibody testing (IFAT), direct
78 microscopy and ssu-rRNA quantitative polymerase chain reaction (qPCR) are the standard
79 methods for detecting *G. duodenalis*, although many diagnostic laboratories rely on
80 microscopy for detection due to cost and established pipelines [28]. Microscopy can lack
81 sensitivity when parasitaemia is low (which is common) or where expertise is lacking,
82 indicating a switch to immunological assays or qPCR in diagnostic settings may be preferable
83 to assess accurately the presence of the parasite [29]. However, it should be appreciated
84 that although qPCR sensitively detects *Giardia* nucleic acid, a positive test result does not
85 necessarily confirm the presence of viable parasite cells. Routine qPCR-based detection
86 methods are also unsuitable for determining the relationships between isolates as they do
87 not provide detailed genetic information [30]. Over the years, several molecular markers
88 have been developed to create a **multilocus sequence typing (MLST)** panel to investigate
89 the molecular phylogeny of *G. duodenalis*. These involve targeted PCR and subsequent
90 sequencing of genes that are relatively stable but possess some degree of variability for
91 differentiating isolates. The most commonly used regions of the genome are the loci
92 encoding β -giardin (*bg*) [31], triosephosphate isomerase (*tpi*) [32] and glutamate
93 dehydrogenase (*gdh*) [33,34]. Of these three primary markers, *tpi* displays the most
94 polymorphisms in the currently sequenced population in terms of substitutions per

95 nucleotide site ($\pi = 0.12$) and *bg* the least ($\pi = 0.03$), with *gdh* intermediate between the
96 two ($\pi = 0.06$) [35]. There are also some rarely used loci that are more difficult to amplify
97 than the typical markers, including the internal transcribed spacer (*its1*) and elongation
98 factor 1 (*ef1*) [36,37]. In common with other parasite species, PCR and sequencing of the
99 ssu-rRNA region is also employed for molecular genotyping [35]. Amplification success for
100 this region can be higher than other PCR targets due to being multi-copy, making it highly
101 sensitive and ideal for identification [38]. However, single-copy markers are still commonly
102 employed due to the relatively low discriminatory power of the ssu-rRNA region [35] and
103 unusually high GC content that can lead to issues with specificity [39,40]. Further analysis
104 has shown that assemblage B isolates display greater polymorphism than other strains at
105 the commonly used marker sites, possessing higher ASH within individual parasites and
106 greater allelic diversity in the population [41,42]. Infections with multiple assemblages [43–
107 45] or sub-assemblages [46] can also occur in humans and animals, affecting estimates of
108 heterozygosity. Furthermore, it appears that mixed genotypic infections can affect infection
109 dynamics, such as increasing cyst shedding [44]. However, it is unclear how often mixed
110 *Giardia* infections occur as they may only be detectable after sub-cloning and sequencing at
111 a depth able to detect low levels of ASH [41].

112 **Current methods provide insufficient resolution**

113 MLST approaches using targeted PCR with sequencing of amplicons have largely validated
114 the assemblage model, leading to the proposal that the assemblages should be formally re-
115 defined as species [47]. However, as the current markers do not provide the resolution
116 required to determine accurately relationships between isolates beyond assemblages, their
117 effectiveness in the public health sphere has been limited. While putative sub-assemblages

118 have been defined within assemblage A (AI–III) [46], the framework describing sub-
119 structuring within assemblage B appears less robust [35]. There are also situations in which
120 there is a lack of concurrence between the different markers that may be due to their low
121 discriminatory power [48,49]. For example, there is only a single nucleotide difference that
122 discriminates between the allele subtypes AI and AII within the *bg* amplicon and two for the
123 corresponding *tpi* subtypes [35]. These issues are clearly demonstrated by recent high-
124 resolution analysis that used an MLST consisting of six markers to examine assemblage A
125 isolates [46]. While delineation into three distinct sub-assemblages was supported,
126 individual markers were less stable and showed conflicting results when examined in
127 isolation. This was attributed to potential recombination within the population. Similar
128 incongruities were noted in a recent study of primate *Giardia* isolates; the current
129 assemblage model could not be reliably reproduced with *ssu-rRNA* data, likely due to the
130 low resolution of the marker [50]. There are also issues with the reliability of PCR assays
131 targeting single copy genes and it is common for only one gene to amplify. Success rates
132 vary from 11–91% across the different markers depending on the study [38]. Mixed
133 infections and ASH can also make it impossible to infer alleles from direct PCR sequencing
134 and it is necessary to use laborious transformation and cloning protocols before sequencing.
135 These are often difficult and costly to implement in a diagnostic setting. This lack of
136 reliability is likely due in part to the large amounts of contaminating DNA and inhibitors
137 found in faecal material, compounded by the variable number of *G. duodenalis* cysts present
138 [51,52]. However, it is also likely that there is a degree of sequence variability present in the
139 genes affecting primer binding sites and amplification success (Box 1 and Figure 2). It is
140 therefore probable that a great deal of genetic diversity in the *Giardia* population is being
141 overlooked due to the specificity of the primers used and the difficulties in amplifying from

142 faecal material. As such, the currently available marker-based system for understanding the
143 molecular phylogeny of *G. duodenalis* is limited in scope and does not provide a high level of
144 genetic discrimination. This makes it virtually impossible to identify reliably transmission
145 routes, reservoirs and relationships between strains, hampering public health efforts to
146 control giardiasis.

147 Investigating the epidemiology of *Giardia* infections

148 The lack of high-resolution genotyping tools also limits the ability to answer fundamental
149 biological questions concerning the parasite, many of which have wider effects on
150 understanding transmission and controlling disease. For example, a large number of
151 companion and livestock animals are infected with *G. duodenalis*, including assemblages
152 that can infect humans [53]. Although in some cases disease manifestation can be severe,
153 the typical clinical impact for animals appears to be low and may often not be associated
154 with clinical signs [54]. While companion animals appear more likely to be infected with
155 species-specific assemblages (C/D in dogs, F in cats), they can also be infected with
156 assemblages A and B. However, whether these actually pose a zoonotic risk is inherently
157 difficult to ascertain due to the low resolution of current markers. Several studies have
158 shown that animals and humans can share genotypes [55] and even sub-assemblages
159 [42,56–61], but incomplete MLSTs, in addition to the low resolution and incongruences
160 between markers, mean these data cannot be definitive. Indeed, many studies rely on the
161 use of a single marker, despite this being inadequate to group isolates reliably [35,41,50,62].
162 Instead, identifying *G. duodenalis* transmission between humans and animals has been
163 inferred using classical epidemiological studies and indirect observations. For example,
164 wide-scale vaccination of dogs in a deprived community in Argentina led to a corresponding

165 decrease in the prevalence of *Giardia* in the local children [63]. Additionally, epidemiological
166 analyses in India found a highly significant association between the prevalence of *G.*
167 *duodenalis* in humans, dog ownership and the presence of a *G. duodenalis*-positive dogs in
168 the same household [37]. Similar links were found between dog ownership and human
169 infection with assemblage A in a United Kingdom setting [64]. However, no link has been
170 found in other communities [65] and it likely that the epidemiology and zoonotic risk of
171 *Giardia* infections vary in different locations. This diversity of epidemiological contexts
172 underlines the need for novel high-resolution genotyping methods which can be applied to
173 reveal the particular transmission pathways in action in different areas.

174 **Population genetic structure of *Giardia***

175 Another important aspect of *G. duodenalis* biology that cannot be resolved with the current
176 molecular tools is the role that sexual recombination plays in creating diversity in natural
177 populations of the parasite. Although seemingly an academic question, this issue is of
178 practical importance as the occurrence of genetic exchange in pathogen populations can
179 have a significant impact on disease epidemiology. For example, in asexual organisms only
180 rare mutations at specific loci or horizontal gene transfers can provide new genotypes that
181 may lead to drug resistance or increased virulence. Conversely, sexual organisms are able to
182 produce new genotypes constantly through meiosis and chromosomal re-assortment,
183 allowing alleles conferring a fitness advantage to spread in the population. This in turn
184 allows pathogens to adapt and exploit new conditions. In diagnostic and public health
185 settings, sexual recombination also affects the ability to track outbreaks and identify
186 transmission networks by disrupting the genotypes involved. Although *G. duodenalis*
187 possesses many of the genes for meiosis [66], sexual reproduction has never directly been

188 observed and examination of **linkage disequilibrium** among isozymes suggests *G.*
189 *duodenalis* is asexual [67]. There are hints that the parasite may not be completely asexual
190 and sexual recombination may simply be a rare event [14,21]. In particular, extensive
191 examination of the genetics of *G. duodenalis* from a single household found evidence for the
192 reassortment of alleles between infections, suggesting sexual recombination [68]. Similar
193 reassortment was suggested by a high-resolution study of assemblage A isolates that also
194 indicated possible cross-assemblage recombination with assemblage E [46]. Horizontal gene
195 transfer has also been documented between assemblages A and B [69,70].

196 An alternative explanation for the low levels of variance and heterozygosity observed in *G.*
197 *duodenalis* is the utilization of a **parasexual cycle** during reproduction, similar to many fungi
198 [71]. A parasexual cycle differs from meiosis in that it involves the fusing of two diploid
199 parent cells prior to genetic exchange rather than haploid gametes. To return to a diploid
200 state there must be a reduction in chromosomal number after this process. Microscopic
201 evidence has shown that within *G. duodenalis* cysts, nuclear fusion and genetic exchange
202 can occur during the transition from the 4x2N to the 4x4N stage (Figure 1B), although
203 without the loss of chromosomes [72]. This unique parasexual cycle could act to decrease
204 heterozygosity within the *G. duodenalis* population, reducing the negative effects associated
205 with deleterious mutations that accumulate in asexual eukaryotes [73]. It can also lead to
206 the generation of new allele combinations, emulating some of the benefits of true sexual
207 recombination. However, as this is essentially a form of self-fertilization (an extreme form of
208 inbreeding), the system can only slow down the accumulation of mutations rather than
209 eliminate them completely. Additionally, a parasexual cycle cannot explain the apparent
210 recombination observed between *Giardia* isolates across assemblages and sub-assemblages
211 [46,68–70], nor incidences of **lateral gene transfer** from bacteria and the host [14].

212 Alternatively, *G. duodenalis* may utilize large-scale **gene conversion** (evidenced by long-
213 range **loss of heterozygosity (LOH)**) achieved through homologous recombination events to
214 compensate for the build-up of deleterious mutations, similar to that described for the
215 asexual parasite *Trypanosoma brucei gambiense* [74]. It is currently unclear if the large
216 regions of homozygosity found in *G. duodenalis* genomes are due to loss of heterozygosity.
217 Irrespective of the method, it seems likely that some form of recombination occurs in *G.*
218 *duodenalis*. Higher-resolution markers or wide-spread sequencing will make it easier to
219 understand how common the phenomenon is and what the effects may be on the molecular
220 epidemiology of *Giardia* infections. This is further supported by a recent study that found
221 evidence for recombination between assemblage A sub-assemblages using six markers [46].
222 However, it is likely that infrequent recombination would affect estimates of how related
223 individuals are, complicating interpretation.

224 **A need for new genotyping tools**

225 Together, these issues indicate a need for more robust tools for genotyping *G. duodenalis* to
226 understand better the molecular epidemiology of the disease and the biology of the
227 parasite to improve outbreak management. The recent publication of updated reference
228 genomes for *G. duodenalis* [75] and *G. muris* [17] provides more complete scaffolds to build
229 upon and a well-characterized outgroup for comparison, contributing to these aims.
230 However, the development of new tools depends on collecting a large and diverse selection
231 of sequenced isolates to capture the diversity in the field more fully. Previously, sequencing
232 of *G. duodenalis* samples has been restricted due to the limitations of sampling from faecal
233 material and the requirement to adapt strains to axenic culture [14,19–21]. This adds
234 significant cost, is labour intensive and introduces time delays to sequencing efforts. It also

235 ensures that only culturable strains can be sequenced, introducing potential bias, although
236 assemblage-specific techniques may improve axenic culture techniques in the future.
237 Comparative genomic analysis may provide information that would improve the axenic
238 culture of specific assemblages, such as the recent analysis of assemblages C and D that
239 identified assemblage-specific genes [18]. Several clinical isolates have recently been
240 sequenced without axenic culture by concentrating cysts from clinical samples [76]. This
241 approach may have limited effectiveness in many situations due to the requirement of a
242 large number of starting cysts (often difficult to obtain in a diagnostic setting) and also
243 results in highly variable sequencing quality and coverage. Several new technologies are
244 now reaching maturity that may allow the rapid whole-genome sequencing (WGS) of *G.*
245 *duodenalis* isolates from the small amount of starting material available in the clinical
246 diagnostic setting. Accurate genomes that represent the individual assemblages would also
247 assist in resequencing efforts in samples with low starting material. For many years this was
248 limited to assemblages A, B and E, although genomes for assemblages C and D have recently
249 been added as a resource for the community [18].

250 **Whole genome sequencing of *Giardia***

251 Central to efforts to sequence *G. duodenalis* clinical isolates are affordable and relatively
252 simple sequencing platforms that can be inserted into diagnostic pathways with little
253 disruption. These technologies have led to the average cost of sequencing falling from
254 \$1,000 per megabase in 2009 to \$0.01 in 2019. Costs are predicted to fall further with the
255 drive to perform WGS routinely for certain pathogens to generate epidemiological data and
256 to assist the management of outbreaks. Indeed, wider deployment of Illumina NovaSeq and
257 third generation long-read sequencing have recently been used to update the *G. duodenalis*

258 reference genome [75]. The long-term aim would be user-friendly sequencing machines that
259 could be deployed at the benchtop and used by non-specialist scientists in diagnostic
260 laboratories. While we are still some way from this goal, and even upcoming “black box”
261 technologies (such as Seeplex or Filmarray) only detect pathogens rather than genotype
262 them, on-site rapid sequencing has shown promise in improving the management of
263 bacterial and viral outbreaks by enhancing throughput, reproducibility and sensitivity. It has
264 also led to a rapid expansion in the number of detectable genotypes and new strategies to
265 understand the molecular epidemiology of these diseases [77]. This in turn has led to an
266 improvement in identifying infectious agents and sources, tracking outbreaks and
267 monitoring drug resistance markers in infected individuals who do not respond to
268 treatment. We suggest similar efforts should be made to build a substantial collection of
269 sequenced samples from multiple centres across the globe to capture the diversity of *G.*
270 *duodenalis* in clinical, veterinary and environmental samples, leading to better management
271 of clusters/outbreaks, reservoirs and drug resistance. To avoid the bottleneck of adapting
272 strains to culture, several approaches have the potential to be developed to allow
273 sequencing of isolates directly from faecal samples. For example, researchers in a recent
274 study used a combination of cytometric sorting and single-cell whole-genome amplification
275 to sequence assemblage C and D isolates from dogs, neither of which have been successfully
276 cultured [18]. This revealed numerous genes that may be linked to host specificity and
277 highlighted important differences in heterozygosity between the assemblages. Another
278 promising technology is exome capture, an approach using biotinylated DNA or RNA ‘baits’
279 to capture DNA fragments from a target genome. This has successfully been used to identify
280 and sequence material with a large amount of contaminating DNA, including enteric
281 pathogens from faeces [78].

282 Making sense of the genomic data

283 If the issues of concentrating and purifying cysts to obtain sufficient quantity and quality of
284 *G. duodenalis* DNA for sequencing are overcome, the next concern that limits the
285 development of high-resolution genotyping markers becomes collating and analysing the
286 large amounts of genomic data. A centralized global database will be required to develop a
287 standardized set of markers efficiently, either by adapting current resources like GiardiaDB
288 [79] or developing a dedicated system that receives MLST or other forms of sequence data.
289 Several such databases have emerged that collate data from bacterial and viral sources,
290 such as Enterobase [80], PubMLST and the European Nucleotide Archive that facilitate
291 standards used for MLST genotyping. Similar efforts have been established in the past for
292 *Giardia* species, for example ZOOPNET [55], however only now is the technology maturing
293 sufficiently to meet the ambitions of the community for research and clinical applications.
294 While a diagnostic panel of single nucleotide polymorphisms would provide the highest
295 resolution for discriminating *G. duodenalis* genotypes, the most widely deployable output in
296 the first instance will be additional MLST loci that expand on the current markers to increase
297 reliability and resolution. These would ideally target genes or regions without indels that
298 would cause frame shift mutations, making them more amenable to direct sequencing and
299 avoiding cloning procedures. Direct sequencing is able to identify heterozygous positions
300 across each of the four genomes present in a single *Giardia* isolate, providing extra
301 discriminatory information [41]. Indeed, it may be preferable to target heterozygous regions
302 to identify potential recombination events occurring between generations. Alternatively, if
303 it is shown that LOH occurs in *G. duodenalis* to reduce deleterious alleles, identifying and
304 contrasting such regions would also serve as a means to establish relationships between
305 strains. In addition, a selection of genes that are under a range of selection pressures would

306 be ideal to provide different temporal resolution. This may entail using markers with
307 relatively high rates of mutation to track close relationships, while using slower evolving
308 genes to elucidate more ancestral relationships. The power of an expanded MLST panel with
309 higher discriminatory power has recently been demonstrated using a combination of six
310 markers, revealing evidence for recombination and zoonotic transfer in assemblage A
311 isolates [46]. However, increasing the number of markers further and improving reliability
312 across all of the different assemblages would allow the collective effort of the *Giardia*
313 community to quantify the degree of zoonotic transmission in different epidemiological
314 contexts and to identify environmental or animal reservoirs of infection.

315 [The application of genomics to clinical isolates](#)

316 The ability to link closely related *G. duodenalis* isolates within a short period of time would
317 allow potential outbreaks to be rapidly identified and effectively managed and could also be
318 used to identify drug-resistant strains. This approach is already in use for other pathogens
319 including tuberculosis, *Salmonella* spp. and *E. coli* O157 [81]. Due to selective testing
320 protocols largely based on patient travel history, there is potential for under-detection of
321 the parasite in clinical samples and under-reporting of domestically-acquired cases, an issue
322 recently highlighted in Scotland [82]. Compared to other pathogens, limited resources are
323 directed towards *Giardia* surveillance activities and for this reason it may be hypothesized
324 that public health systems would lack the power to detect small-scale endemic outbreaks
325 should they occur. This is particularly the case if these outbreaks had low case numbers and
326 were not associated with a clear 'point source', such as a water contamination event. For
327 these reasons, having the capacity to detect outbreaks routinely as part of a clinical
328 genomics laboratory service would represent a major step forward for public health [12].

329 PCR and Sanger sequencing-based MLST approaches have the benefit of being more easily
330 inserted into current laboratory pathways [83,84], are rapid, cost-effective and are also
331 more likely to be adopted in lower-to-middle income countries that lack the capacity to
332 perform large amounts of sequencing. As sequencing technology reaches greater
333 penetration, clinical diagnostic services could begin to incorporate high-throughput
334 sequencing into their pipelines while maintaining backwards compatibility with established
335 MLST systems [84]. The cooperation of low, middle- and higher-income countries will not
336 only be essential to identify both endemic outbreaks and reservoirs but also distinguish
337 cases caused by 'foreign' genotypes of *Giardia* that have been imported through
338 international travel. Working in such a broadly collaborative manner will undoubtedly raise
339 issues in the sharing of public health data, the policies for which can vary widely between
340 countries. Fortunately, efforts such as the Global Alliance for Genomics and Health are
341 working to facilitate such programmes and their recommendations have been adopted by a
342 number of health services worldwide [85].

343 [Using genomics to understand the biology of *Giardia*](#)

344 Although the collection of large amounts of sequencing data and the development of more
345 robust sets of MLSTs will directly impact the management of giardiasis, these data will also
346 contribute to answering several long-standing questions concerning the biology of the
347 parasite that have implications for the disease. For example, large numbers of genomic or
348 high-resolution MLST sequences would reveal the degree to which allelic recombination
349 occurs between generations of parasites, especially if isolates were closely linked in terms of
350 geographical location and time of sampling. The differences between generations would
351 also demonstrate whether recombination was occurring between individuals or a

352 parasexual cycle was being utilized [72]. Determining the amount of recombination
353 occurring in the field is important as it directly impacts our understanding of transmission
354 networks and the likelihood of positive mutations becoming fixed in the population. These
355 data would also confirm which assemblages are true species and no longer share genetic
356 information, and those that have host-specific adaptations which limit their zoonotic
357 potential. For example, several genes have been identified in assemblage C isolates that are
358 suggested to be involved in host-specificity [18]. Finally, the capacity to genotype large
359 numbers of isolates accurately has the potential to reveal associations between parasite
360 genes and phenotypes. This will allow forward genetic techniques to be used in *G.*
361 *duodenalis* for the first time, making it easier to link genotype to phenotype. Similarly, the
362 ongoing refinement of single-cell genomics and transcriptomics also provides a tool to
363 examine important biological questions in *Giardia* [86]. This would include identifying genes
364 that distinguish between drug resistance and treatment failure [87] and identifying
365 genotypes involved in more severe sequelae [11]. These approaches along with other
366 advances in functional analysis will, to some extent, compensate for the lack of a reverse
367 genetic framework for *Giardia* which has stifled research in this area [88]. Fortunately, in-
368 roads are being made with the development of CRISPR/Cas9-mediated gene knockdown
369 protocols, although the capacity for complete knockout remains elusive [89,90].

370 The current genetic contribution to drug resistance is unclear [91] and appears to be largely
371 linked to transcriptional changes mediated by epigenetic factors [87]. However, there are
372 numerous polymorphisms in several of the genes believed to be involved [92]. This suggests
373 that if associating polymorphisms are identified in these candidate genes then there is the
374 capacity to identify and distinguish cases of true drug-resistance from treatment failure for
375 alternative reasons. The application of WGS to clinical isolates would also reveal whether *de*

376 *novo* positively selected mutations, including LOH events, arise *in vivo* and what role they
377 may play in drug resistance. This knowledge would lead to an improvement in patient
378 treatment by allowing alternative drug regimens to be followed immediately rather than
379 waiting for treatment failure. If an effective alternative treatment can be utilized quickly in
380 such cases, this would reduce the selective power of the ineffective treatment and limit the
381 spread of resistant genotypes, therefore benefiting wider public health. To date, no allelic
382 variants of genes have been identified that associate with different clinical outcomes of *G.*
383 *duodenalis* infection, despite symptoms ranging from asymptomatic carriage to long-term
384 IBS [11]. Preliminary data is largely ambiguous, with conflicting genotypes associating with
385 the development of symptoms [2,93]. Again, the use of a publicly available pathogen
386 database (or expanding current resources such as GiardiaDB) that integrates data from
387 forward genetic screens and association studies would facilitate the identification of the
388 genes involved. However, this would require a degree of clinical information being made
389 available alongside the genetic information, complicating data sharing across jurisdictions. It
390 will also be important to determine the molecular profile of isolates from asymptomatic
391 cases, raising further ethical and logistical issues. The input that host and parasite genetics
392 have in determining outcome is important to establish as these asymptomatic cases may
393 represent a large and overlooked reservoir of infection for susceptible individuals, again
394 impacting public health.

395 **Concluding Remarks**

396 In summary, there has been a long-held view that new genotyping markers are required for
397 *G. duodenalis* to address numerous issues (Outstanding Questions Box). New sequencing
398 technologies based on genome capture and single cell sequencing mean that it is now

399 possible to achieve these aims using clinical samples. However, successfully expanding the
400 MLST framework for *G. duodenalis* will require cooperation across the research, medical and
401 veterinary communities to develop a consistent set of standards and methods to avoid
402 replicating effort and maximising return. It will also benefit from establishing a centralised
403 database to collate and process data to deliver tangible outcomes that benefit public health.
404 This does not necessarily require the generation of new tools, as current resources such as
405 GiardiaDB may be expanded to perform a wider role. The routine application of WGS to
406 clinical samples in the public health sphere would allow a genomics-led approach to
407 outbreak detection, which contrasts to the 'response mode' approach currently taken
408 where only large-scale outbreaks identified by other surveillance activities are genetically
409 characterized. Clinical genomics would also allow drug-resistant isolates to be
410 comprehensively genotyped, determining whether resistant lineages are circulating and
411 whether *de novo*, positively selected mutants play a role in this poorly understood
412 phenomenon. If successful, these approaches will greatly improve the global effort to
413 reduce *Giardia* infections effectively and minimize outbreaks, and also answer long-standing
414 questions concerning the biology of these unique eukaryotes.

415 Acknowledgements

416 The figures use art adapted from Servier Medical Art under a Creative Commons Attribution
417 3.0 Unported License <https://creativecommons.org/licenses/by/3.0/>).

418 References

- 419 1 Torgerson, P.R. *et al.* (2015) World Health Organization Estimates of the Global and Regional
420 Disease Burden of 11 Foodborne Parasitic Diseases, 2010: A Data Synthesis. *PLoS Med* 12,
421 e1001920
- 422 2 Jerez Puebla, L.E. *et al.* (2017) Molecular analysis of *Giardia duodenalis* isolates from symptomatic
423 and asymptomatic children from La Habana, Cuba. *Parasite Epidemiology and Control* 2, 105–113

- 424 3 Muadica, A.S. *et al.* (2020) Molecular Diversity of *Giardia duodenalis*, *Cryptosporidium* spp. and
425 *Blastocystis* sp. in Asymptomatic School Children in Leganés, Madrid (Spain). *Microorganisms* 8,
426 466
- 427 4 Oliveira-Arbex, A.P. *et al.* (2016) Genotyping of *Giardia duodenalis* isolates in asymptomatic
428 children attending daycare centre: evidence of high risk for anthroponotic transmission.
429 *Epidemiol. Infect.* 144, 1418–1428
- 430 5 Ramírez, J.D. *et al.* (2015) Molecular diagnosis and genotype analysis of *Giardia duodenalis* in
431 asymptomatic children from a rural area in central Colombia. *Infection, Genetics and Evolution* 32,
432 208–213
- 433 6 Rogawski, E.T. *et al.* (2017) Determinants and Impact of *Giardia* Infection in the First 2 Years of
434 Life in the MAL-ED Birth Cohort. *Journal of the Pediatric Infectious Diseases Society* 6, 153–160
- 435 7 Fink, M.Y. and Singer, S.M. (2017) The Intersection of Immune Responses, Microbiota, and
436 Pathogenesis in Giardiasis. *Trends in Parasitology* 33, 901–913
- 437 8 Allain, T. and Buret, A.G. (2020) Pathogenesis and post-infectious complications in giardiasis. In
438 *Advances in Parasitology* 107pp. 173–199, Elsevier
- 439 9 Beatty, J.K. *et al.* (2017) *Giardia duodenalis* induces pathogenic dysbiosis of human intestinal
440 microbiota biofilms. *International Journal for Parasitology* 47, 311–326
- 441 10 Barash, N.R. *et al.* (2017) *Giardia* Alters Commensal Microbial Diversity throughout the
442 Murine Gut. *Infect. Immun.* 85, e00948-16, /iai/85/6/e00948-16.atom
- 443 11 Hanevik, K. *et al.* (2009) Development of functional gastrointestinal disorders after *Giardia*
444 *lamblia* infection. *BMC Gastroenterol* 9, 27
- 445 12 Efstratiou, A. *et al.* (2017) Waterborne transmission of protozoan parasites: Review of
446 worldwide outbreaks - An update 2011–2016. *Water Research* 114, 14–22
- 447 13 Adam, E.A. *et al.* (2016) Giardiasis outbreaks in the United States, 1971–2011. *Epidemiol.*
448 *Infect.* 144, 2790–2801
- 449 14 Morrison, H.G. *et al.* (2007) Genomic Minimalism in the Early Diverging Intestinal Parasite
450 *Giardia lamblia*. *Science* 317, 1921–1926
- 451 15 Karnkowska, A. *et al.* (2016) A Eukaryote without a Mitochondrial Organelle. *Current Biology*
452 26, 1274–1284
- 453 16 Bernander, R. *et al.* (2001) Genome ploidy in different stages of the *Giardia lamblia* life cycle.
454 *Cell Microbiol* 3, 55–62
- 455 17 Xu, F. *et al.* (2020) The compact genome of *Giardia muris* reveals important steps in the
456 evolution of intestinal protozoan parasites. *Microbial Genomics* DOI: 10.1099/mgen.0.000402
- 457 18 Kooyman, F.N.J. *et al.* (2019) Whole-genome sequencing of dog-specific assemblages C and
458 D of *Giardia duodenalis* from single and pooled cysts indicates host-associated genes. *Microbial*
459 *Genomics* 5,
- 460 19 Franzén, O. *et al.* (2009) Draft Genome Sequencing of *Giardia intestinalis* Assemblage B
461 Isolate GS: Is Human Giardiasis Caused by Two Different Species? *PLoS Pathog* 5, e1000560
- 462 20 Ankarklev, J. *et al.* (2015) Comparative genomic analyses of freshly isolated *Giardia*
463 *intestinalis* assemblage A isolates. *BMC Genomics* 16, 697
- 464 21 Jerlström-Hultqvist, J. *et al.* (2010) Genome analysis and comparative genomics of a *Giardia*
465 *intestinalis* assemblage E isolate. *BMC Genomics* 11, 543
- 466 22 Mayrhofer, G. *et al.* (1995) Division of *Giardia* isolates from humans into two genetically
467 distinct assemblages by electrophoretic analysis of enzymes encoded at 27 loci and comparison
468 with *Giardia muris*. *Parasitology* 111, 11–17
- 469 23 Homan, W.L. *et al.* (1992) Comparison of *Giardia* isolates from different laboratories by
470 isoenzyme analysis and recombinant DNA probes. *Parasitol Res* 78, 316–323
- 471 24 Keulen, H. *et al.* (1995) A Three Nucleotide Signature Sequence in Small Subunit rRNA
472 Divides Human *Giardia* in Two Different Genotypes. *J Eukaryotic Microbiology* 42, 392–394

- 473 25 Soliman, R.H. *et al.* (2011) Identification of a novel Assemblage B subgenotype and a
474 zoonotic Assemblage C in human isolates of *Giardia intestinalis* in Egypt. *Parasitology*
475 *International* 60, 507–511
- 476 26 Gelanew, T. *et al.* (2007) Molecular characterization of human isolates of *Giardia duodenalis*
477 from Ethiopia. *Acta Tropica* 102, 92–99
- 478 27 Zahedi, A. *et al.* (2017) Molecular typing of *Giardia duodenalis* in humans in Queensland –
479 first report of Assemblage E. *Parasitology* 144, 1154–1161
- 480 28 Alexander, C.L. *et al.* (2017) An audit of *Cryptosporidium* and *Giardia* detection in Scottish
481 National Health Service Diagnostic Microbiology Laboratories. *Epidemiol. Infect.* 145, 1584–1590
- 482 29 Soares, R. and Tasca, T. (2016) Giardiasis: an update review on sensitivity and specificity of
483 methods for laboratorial diagnosis. *Journal of Microbiological Methods* 129, 98–102
- 484 30 Laude, A. *et al.* (2016) Is real-time PCR-based diagnosis similar in performance to routine
485 parasitological examination for the identification of *Giardia intestinalis*, *Cryptosporidium parvum*
486 / *Cryptosporidium hominis* and *Entamoeba histolytica* from stool samples? Evaluation of a new
487 commercial multiplex PCR assay and literature review. *Clinical Microbiology and Infection* 22,
488 190.e1-190.e8
- 489 31 Cacciò, S.M. *et al.* (2002) Sequence analysis of the β -giardin gene and development of a
490 polymerase chain reaction–restriction fragment length polymorphism assay to genotype *Giardia*
491 *duodenalis* cysts from human faecal samples. *International Journal for Parasitology* 32, 1023–
492 1030
- 493 32 Sulaiman, I.M. *et al.* (2003) Triosephosphate Isomerase Gene Characterization and Potential
494 Zoonotic Transmission of *Giardia duodenalis*. *Emerg. Infect. Dis.* 9, 1444–1452
- 495 33 Cacciò, S.M. *et al.* (2008) Multilocus genotyping of *Giardia duodenalis* reveals striking
496 differences between assemblages A and B. *International Journal for Parasitology* 38, 1523–1531
- 497 34 Monis, P.T. *et al.* (1996) Molecular genetic analysis of *Giardia intestinalis* isolates at the
498 glutamate dehydrogenase locus. *Parasitology* 112, 1–12
- 499 35 Wielinga, C.M. and Thompson, R.C.A. (2007) Comparative evaluation of *Giardia duodenalis*
500 sequence data. *Parasitology* 134, 1795–1821
- 501 36 Cacciò, S.M. *et al.* (2010) Identification of *Giardia* species and *Giardia duodenalis*
502 assemblages by sequence analysis of the 5.8S rDNA gene and internal transcribed spacers.
503 *Parasitology* 137, 919–925
- 504 37 Traub, R.J. *et al.* (2004) Epidemiological and molecular evidence supports the zoonotic
505 transmission of *Giardia* among humans and dogs living in the same community. *Parasitology* 128,
506 253–262
- 507 38 Thompson, R.C.A. and Ash, A. (2016) Molecular epidemiology of *Giardia* and
508 *Cryptosporidium* infections. *Infection, Genetics and Evolution* 40, 315–323
- 509 39 Rochelle, P.A. *et al.* (1997) Comparison of primers and optimization of PCR conditions for
510 detection of *Cryptosporidium parvum* and *Giardia lamblia* in water. *Appl. Environ. Microbiol.* 63,
511 106–114
- 512 40 Weiss, J.B. *et al.* (1992) Classification of subgroups of *Giardia lamblia* based upon ribosomal
513 RNA gene sequence using the polymerase chain reaction. *Mol. Biochem. Parasitol.* 54, 73–86
- 514 41 Ankarklev, J. *et al.* (2012) Allelic sequence heterozygosity in single *Giardia* parasites. *BMC*
515 *Microbiol* 12, 65
- 516 42 Lalle, M. *et al.* (2005) Genetic heterogeneity at the β -giardin locus among human and animal
517 isolates of *Giardia duodenalis* and identification of potentially zoonotic subgenotypes.
518 *International Journal for Parasitology* 35, 207–213
- 519 43 Almeida, A. *et al.* (2010) Genotyping of *Giardia duodenalis* Cysts by New Real-Time PCR
520 Assays for Detection of Mixed Infections in Human Samples. *AEM* 76, 1895–1901
- 521 44 Kohli, A. *et al.* (2008) *Giardia duodenalis* assemblage, clinical presentation and markers of
522 intestinal inflammation in Brazilian children. *Transactions of the Royal Society of Tropical*
523 *Medicine and Hygiene* 102, 718–725

524 45 Geurden, T. *et al.* (2008) Mixed *Giardia duodenalis* assemblage A and E infections in calves.
525 *International Journal for Parasitology* 38, 259–264

526 46 Ankarklev, J. *et al.* (2018) A novel high-resolution multilocus sequence typing of *Giardia*
527 *intestinalis* Assemblage A isolates reveals zoonotic transmission, clonal outbreaks and
528 recombination. *Infection, Genetics and Evolution* 60, 7–16

529 47 Monis, P.T. *et al.* (2009) Variation in *Giardia*: towards a taxonomic revision of the genus.
530 *Trends in Parasitology* 25, 93–100

531 48 Robertson, L.J. *et al.* (2006) Application of Genotyping during an Extensive Outbreak of
532 Waterborne Giardiasis in Bergen, Norway, during Autumn and Winter 2004. *Applied and*
533 *Environmental Microbiology* 72, 2212–2217

534 49 Bonhomme, J. *et al.* (2011) Limitations of *tpi* and *bg* genes sub-genotyping for
535 characterization of human *Giardia duodenalis* isolates. *Parasitology International* 60, 327–330

536 50 Brynildsrud, O. *et al.* (2018) *Giardia duodenalis* in primates: Classification and host specificity
537 based on phylogenetic analysis of sequence data. *Zoonoses Public Health* 65, 637–647

538 51 Elwin, K. *et al.* (2014) *Giardia duodenalis* typing from stools: a comparison of three
539 approaches to extracting DNA, and validation of a probe-based real-time PCR typing assay.
540 *Journal of Medical Microbiology* 63, 38–44

541 52 Miller, K.M. and Sterling, C.R. (2007) Sensitivity of Nested PCR in the Detection of Low
542 Numbers of *Giardia lamblia* Cysts. *Applied and Environmental Microbiology* 73, 5949–5950

543 53 Thompson, R.C.A. (2004) The zoonotic significance and molecular epidemiology of *Giardia*
544 and giardiasis. *Veterinary Parasitology* 126, 15–35

545 54 Thompson, R.C.A. *et al.* (2008) The public health and clinical significance of *Giardia* and
546 *Cryptosporidium* in domestic animals. *The Veterinary Journal* 177, 18–25

547 55 Sprong, H. *et al.* (2009) Identification of Zoonotic Genotypes of *Giardia duodenalis*. *PLoS*
548 *Negl Trop Dis* 3, e558

549 56 Volotão, A.C. *et al.* (2007) Genotyping of *Giardia duodenalis* from human and animal
550 samples from Brazil using β -giardin gene: A phylogenetic analysis. *Acta Tropica* 102, 10–19

551 57 Durigan, M. *et al.* (2014) Genetic Diversity of *Giardia duodenalis*: Multilocus Genotyping
552 Reveals Zoonotic Potential between Clinical and Environmental Sources in a Metropolitan Region
553 of Brazil. *PLoS ONE* 9, e115489

554 58 Caseca Volotão, A.C. *et al.* (2011) Giardiasis as zoonosis: between proof of principle and
555 paradigm in the Northwestern region of São Paulo State, Brazil. *The Brazilian Journal of Infectious*
556 *Diseases* 15, 382–383

557 59 Bartley, P.M. *et al.* (2019) Detection of potentially human infectious assemblages of *Giardia*
558 *duodenalis* in fecal samples from beef and dairy cattle in Scotland. *Parasitology* 146, 1123–1130

559 60 Lebbad, M. *et al.* (2011) Multilocus Genotyping of Human *Giardia* Isolates Suggests Limited
560 Zoonotic Transmission and Association between Assemblage B and Flatulence in Children. *PLoS*
561 *Negl Trop Dis* 5, e1262

562 61 Lebbad, M. *et al.* (2010) From mouse to moose: Multilocus genotyping of *Giardia* isolates
563 from various animal species. *Veterinary Parasitology* 168, 231–239

564 62 Wielinga, C. *et al.* (2011) Multi-locus analysis of *Giardia duodenalis* intra-Assemblage B
565 substitution patterns in cloned culture isolates suggests sub-Assemblage B analyses will require
566 multi-locus genotyping with conserved and variable genes. *International Journal for Parasitology*
567 41, 495–503

568 63 Serradell, M.C. *et al.* (2016) Vaccination of domestic animals with a novel oral vaccine
569 prevents *Giardia* infections, alleviates signs of giardiasis and reduces transmission to humans. *npj*
570 *Vaccines* 1, 16018

571 64 Minetti, C. *et al.* (2015) Case-Control Study of Risk Factors for Sporadic Giardiasis and
572 Parasite Assemblages in North West England. *J. Clin. Microbiol.* 53, 3133–3140

573 65 de Lucio, A. *et al.* (2017) No molecular epidemiological evidence supporting household
574 transmission of zoonotic *Giardia duodenalis* and *Cryptosporidium* spp. from pet dogs and cats in
575 the province of Álava, Northern Spain. *Acta Tropica* 170, 48–56

576 66 Ramesh, M.A. *et al.* (2005) A Phylogenomic Inventory of Meiotic Genes. *Current Biology* 15,
577 185–191

578 67 Tibayrenc, M. *et al.* (1990) A clonal theory of parasitic protozoa: the population structures of
579 *Entamoeba*, *Giardia*, *Leishmania*, *Naegleria*, *Plasmodium*, *Trichomonas*, and *Trypanosoma* and
580 their medical and taxonomical consequences. *Proceedings of the National Academy of Sciences*
581 87, 2414–2418

582 68 Cooper, M.A. *et al.* (2007) Population Genetics Provides Evidence for Recombination in
583 *Giardia*. *Current Biology* 17, 1984–1988

584 69 Teodorovic, S. *et al.* (2007) Unusually Low Levels of Genetic Variation among *Giardia lamblia*
585 Isolates. *Eukaryotic Cell* 6, 1421–1430

586 70 Lasek-Nesselquist, E. *et al.* (2009) Genetic Exchange Within and Between Assemblages of
587 *Giardia duodenalis*. *Journal of Eukaryotic Microbiology* 56, 504–518

588 71 Clutterbuck, A.J. (1996) Parasexual recombination in fungi. *J. Genet.* 75, 281–286

589 72 Poxleitner, M.K. *et al.* (2008) Evidence for Karyogamy and Exchange of Genetic Material in
590 the Binucleate Intestinal Parasite *Giardia intestinalis*. *Science* 319, 1530–1533

591 73 Gabriel, W. *et al.* (1993) Muller’s Ratchet and Mutational Meltdowns. *Evolution* 47, 1744–
592 1757

593 74 Weir, W. *et al.* (2016) Population genomics reveals the origin and asexual evolution of
594 human infective trypanosomes. *eLife* 5, e11473

595 75 Xu, F. *et al.* (2020) A chromosome-scale reference genome for *Giardia intestinalis* WB. *Sci*
596 *Data* 7, 38

597 76 Hanevik, K. *et al.* (2015) Whole genome sequencing of clinical isolates of *Giardia lamblia*.
598 *Clinical Microbiology and Infection* 21, 192.e1-192.e3

599 77 Allcock, O.M. *et al.* (2018) BacCapSeq: a Platform for Diagnosis and Characterization of
600 Bacterial Infections. *mBio* 9, e02007-18, /mbio/9/5/mBio.02007-18.atom

601 78 Jones, M.R. and Good, J.M. (2016) Targeted capture in evolutionary and ecological
602 genomics. *Mol Ecol* 25, 185–202

603 79 Aurrecochea, C. *et al.* (2009) GiardiaDB and TrichDB: integrated genomic resources for the
604 eukaryotic protist pathogens *Giardia lamblia* and *Trichomonas vaginalis*. *Nucleic Acids Research*
605 37, D526–D530

606 80 Zhou, Z. *et al.* (2020) The EnteroBase user’s guide, with case studies on *Salmonella*
607 transmissions, *Yersinia pestis* phylogeny, and *Escherichia* core genomic diversity. *Genome Res.* 30,
608 138–152

609 81 Lipworth, S. *et al.* (2019) SNP-IT Tool for Identifying Subspecies and Associated Lineages of
610 *Mycobacterium tuberculosis* Complex. *Emerg. Infect. Dis.* 25, 482–488

611 82 Currie, S.L. *et al.* (2017) Under-reporting giardiasis: time to consider the public health
612 implications. *Epidemiol. Infect.* 145, 3007–3011

613 83 Ibarz Pavón, A.B. and Maiden, M.C.J. (2009) Multilocus Sequence Typing. In *Molecular*
614 *Epidemiology of Microorganisms* 551 (Caugant, D. A., ed), pp. 129–140, Humana Press

615 84 Rossen, J.W.A. *et al.* (2018) Practical issues in implementing whole-genome-sequencing in
616 routine diagnostic microbiology. *Clinical Microbiology and Infection* 24, 355–360

617 85 Rahimzadeh, V. *et al.* (2016) An International Framework for Data Sharing: Moving Forward
618 with the Global Alliance for Genomics and Health. *Biopreservation and Biobanking* 14, 256–259

619 86 Onsbring, H. *et al.* (2020) An efficient single-cell transcriptomics workflow for microbial
620 eukaryotes benchmarked on *Giardia intestinalis* cells. *BMC Genomics* 21, 448

621 87 Ansell, B.R.E. *et al.* (2015) Drug resistance in *Giardia duodenalis*. *Biotechnology Advances* 33,
622 888–901

623 88 Jex, A.R. *et al.* (2020) Recent advances in functional research in *Giardia intestinalis*. In
624 *Advances in Parasitology* 107pp. 97–137, Elsevier

625 89 Lin, Z.-Q. *et al.* (2019) Development of CRISPR/Cas9-mediated gene disruption systems in
626 *Giardia lamblia*. *PLoS ONE* 14, e0213594

627 90 McInally, S.G. *et al.* (2019) Robust and stable transcriptional repression in *Giardia* using
628 CRISPRi. *MBoC* 30, 119–130

629 91 Müller, J. *et al.* (2019) Resistance formation to nitro drugs in *Giardia lamblia*: No common
630 markers identified by comparative proteomics. *International Journal for Parasitology: Drugs and*
631 *Drug Resistance* 9, 112–119

632 92 Saghaug, C.S. *et al.* (2019) Genetic variation in metronidazole metabolism and oxidative
633 stress pathways in clinical *Giardia lamblia* assemblage A and B isolates. *IDR* Volume 12, 1221–
634 1235

635 93 Sahagún, J. *et al.* (2007) Correlation between the presence of symptoms and the *Giardia*
636 *duodenalis* genotype. *Eur J Clin Microbiol Infect Dis* 27, 81–83

637

638 Glossary

639 **18S ssu-rRNA gene:** highly conserved gene encoding ribosomal RNA and commonly used for
640 phylogenetic studies

641 **allelic sequence heterozygosity (ASH):** genetic differences at a genetic locus as assessed
642 across the four different genomes in an individual *Giardia* isolate

643 **cyst:** infective, environmental stage of the parasite

644 **diplomixis:** a unique parasexual recombination cycle that occurs between two nuclei of a
645 *Giardia* cell during encystation

646 **diplomonad:** group of flagellated protozoa with double cells and two nuclei

647 **dysbiosis:** disruption of the gut-microflora

648 **excystoite:** a newly excysted *Giardia* cell with 4×4N ploidy

649 **gene conversion:** transfer of genetic material from an intact chromosomal DNA sequence to
650 a homologous sequence which contains double-strand breaks

651 **inter-nuclei heterozygosity:** the degree of polymorphism between the two nuclei of a
652 *Giardia* cell, which is typically lower than would be expected

653 **isozyme (or isoenzyme):** multiple forms of the same enzyme that differ in amino acid
654 sequence and which can be used as the basis for a typing method

655 **lateral gene transfer:** the horizontal movement of genetic material between organisms
656 distinct from the vertical transmission of DNA from parent to offspring

657 **linkage disequilibrium:** the non-random association of alleles at two or more loci in a
658 population

659 **loss of heterozygosity (LOH):** regions that display no heterozygous sites in a genome

660 **multilocus sequence typing (MLST):** method used to characterize individuals genetically
661 based on the sequence at a number of marker loci distributed throughout the genome

662 **parasexual recombination:** a process genetic recombination utilized by some organisms
663 that does not require the production and fusing of haploid gametes

664 **peroxisome:** membrane-bound organelle found in eukaryotic cells involved in oxidation and
665 lipid metabolism

666 **ploidy:** the number of sets of chromosomes within the cell of an organism

667 **trophozoite:** active 'feeding' form of the parasite located in the small intestine responsible
668 for pathology


669

670 Text Boxes

671 **Box 1. G376 primer annealing site diversity.** The diversity found within the three main
672 genes used to genotype *G. duodenalis* (*bg*, *tpi*, and *gdh*) makes them useful to differentiate
673 assemblages and subtypes. The separate assemblages also display different diversities,
674 allowing a degree of sub-structuring to be observed. However, this diversity may also
675 encompass the primer annealing sites, affecting the amplification success rates for isolates
676 and assemblages. For example, there are 1,598 publicly available *G. duodenalis* sequences
677 that include the annealing site for the commonly used β -giardin primer G376. Within these
678 sequences, there can be up to eight polymorphisms compared to the primer sequence
679 (Figure 2). Assemblage A sequences are the least likely to have polymorphisms, likely
680 reflecting the fact that primers are initially designed using this assemblage. Conversely,
681 assemblages B–H are more likely to contain polymorphisms in the annealing site (most have
682 at least two), making them harder to amplify. In addition, as these public sequences are by
683 definition the products of successful reactions with optimal conditions for promoting
684 amplification, it is reasonable to speculate that many sequences fail to amplify due to
685 polymorphisms in the primer-binding sites and other inhibiting factors.

686


687



689

690 **Key Figure. The unknown aspects of *Giardia duodenalis* molecular epidemiology.** The
 691 parasite *Giardia duodenalis* infects a wide range of mammalian hosts and features a
 692 relatively simple direct life cycle. Despite being one of the most common enteric parasites in
 693 the world, low resolution molecular markers limit research and control efforts in this
 694 important organism. For example, the relationships between clinical isolates cannot
 695 accurately be established, making it difficult to identify outbreaks and trace sources of
 696 disease. Similarly, a role for zoonotic transmission in human disease is also unclear, although
 697 it is suspected based on indirect evidence. Finally, certain aspects of *G. duodenalis* biology
 698 that would affect efforts to control the disease, such as the frequency of sexual or
 699 parasexual recombination, remain ambiguous. In this manuscript, we discuss how new
 700 sequencing technologies and strategies may contribute to a new generation of molecular
 701 markers for *Giardia* that will aid in addressing these questions and contribute to improving
 702 public health.


703



704

Mammalian Gut

705 **Figure 1. An overview of the *G. duodenalis* life cycle.** A) In the mammalian intestinal tract,
 706 binucleate trophozoites cycle between 4N and 8N during vegetative growth. Trophozoites
 707 swept into the large intestine differentiate into cysts and are released into the environment
 708 for direct transmission. During encystation, the two nuclei divide and the DNA replicates,
 709 resulting in a ploidy of 16N. After activation in the mammalian stomach, cysts excyst in the
 710 intestine to release a 16N **excyzoite** with four nuclei. This **excyzoite** divides twice without
 711 DNA replication, resulting in four trophozoites that begin the vegetative cycle in a new host.
 712 B) *G. duodenalis* exhibits a unique parasexual cycle (**diplomixis**) that may contribute to
 713 lower than expected heterozygosity between the two nuclei of the cell. When the 16N cyst
 714 is formed during encystation, genetic exchange can occur between nuclei via homologous
 715 recombination. i) Without diplomixis, **inter-nucleus heterozygosity** is maintained in the
 716 daughter cells. Consequently, inter-nucleus heterozygosity will continue to increase and the
 717 genomes of the two nuclei will diverge. ii) With occasional diplomixis, regions of inter-
 718 nucleus heterozygosity can be transferred, reducing heterozygosity in some of the daughter
 719 cells and slowing the rate of divergence between the two nuclei. In addition, the process can
 720 generate genotypes with new allele combinations, further emulating sexual recombination.



721

722 **Figure 2. β -giardin G376 primer annealing site diversity among assemblages.** For this
 723 analysis, 1,598 publicly available *G. duodenalis* sequences were downloaded and the G376
 724 primer annealing site identified and aligned. The numbers of differences between each
 725 sequenced site and the primer were calculated using the Levenstein distance. The data are
 726 presented for each assemblage, showing that assemblage A sequences have few
 727 polymorphisms in the annealing site compared to the published primer. In contrast,
 728 assemblages B–H have, for the most part, at least two and up to five polymorphisms in total.

729

730

731 **Tables**

732 **Table 1. *Giardia duodenalis* host assemblages**

<i>Giardia</i> Assemblage/Sub-Assemblage	Host	Proposed Nomenclature [47]
A I II III	Humans, non-human primates, canines, felines, other mammals	<i>G. duodenalis</i>
B	Humans, non-human primates, canines, felines, other mammals	<i>G. enterica</i>
C	Canines	<i>G. canis</i>
D	Canines	<i>G. canis</i>
E	Livestock	<i>G. bovis</i>
F	Felines	<i>G. cati</i>
G	Rodents	<i>G. simondi</i>
H	Marine mammals	

733

734